SCHEMBL13888644

SCHEMBL13888644

CCC1OCC(n2ccc(NC(=O)c3ccccc3)nc2=O)C(F)C1O[Si](C)(C)C(C)(C)C

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 1/20 0.46
▸ ABL1 P00519 1/20 0.45
▸ RIN1 Q13671 1/20 0.45
▸ P2RY6 Q15077 2/20 0.42
▸ P2RY14 Q15391 2/20 0.42
▸ NT5E P21589 1/20 0.42
▸ KMT2A Q03164 2/20 0.32
▸ MEN1 O00255 1/20 0.32
▸ P2RY12 Q9H244 1/20 0.32
▸ LMNA P02545 2/20 0.31
▸ HTR1A P08908 1/20 0.31
▸ HTR1D P28221 1/20 0.31
▸ HTR1B P28222 1/20 0.31
▸ HTR1F P30939 1/20 0.31
▸ RAB9A P51151 4/20 0.31
▸ KDM4E B2RXH2 1/20 0.31
▸ NPSR1 Q6W5P4 1/20 0.31
▸ TDP1 Q9NUW8 1/20 0.31
▸ SMN1; SMN2 Q16637 4/20 0.31
▸ NPC1 O15118 3/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2694927 0.87 ABL1 (0.45) POLBABL1RIN1P2RY6P2RY14
SCHEMBL2695020 0.86 SMN1; SMN2 (0.35) POLBABL1RIN1P2RY6P2RY14
SCHEMBL13888640 0.85 ABL1 (0.51) POLBABL1RIN1P2RY6P2RY14
SCHEMBL2694973 0.81 POLB (0.41) POLBABL1RIN1P2RY6P2RY14
SCHEMBL13888641 0.80 PDE3A (0.36) POLBLMNAMAPT
SCHEMBL13381664 0.79 P2RY6 (0.51) POLBABL1RIN1P2RY6P2RY14
SCHEMBL12636396 0.77 P2RY6 (0.46) POLBABL1RIN1P2RY6P2RY14
SCHEMBL31637229 0.75 P2RY6 (0.56) POLBABL1RIN1P2RY6P2RY14
SCHEMBL6694582 0.75 POLB (0.56) POLBABL1RIN1P2RY6P2RY14
SCHEMBL31274854 0.74 POLB (0.53) POLBABL1RIN1P2RY6P2RY14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090092981-A1 TETRAHYDROPYRAN NUCLEIC ACID ANALOGS IONIS PHARMACEUTICALS, INC. 2009-04-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090092981-A1 TETRAHYDROPYRAN NUCLEIC ACID ANALOGS HNRNPM, POLM, RNMT POLB 217/4885ABL1 4331/4885RIN1 1542/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback